Adjuvant therapy as planned in the protocol was prematurely discontinued without evidence of tumour relapse in 25 patients (17.2%) of the 5-FU single-agent group, in 29 patients (20.7%) of the 5-FU plus LEV group, in 52 patients (36.6%) of the 5-FU plus IFN group and in 72 patients (49.7%) of the 5-FU/LEV/IFN triple-agent group. This evidence concerns the gene IFNA1 and neoplasm.